TELA Bio, Inc. is a commercial-stage medical technology company. The Company is focused on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s own anatomy. Its first portfolio of products, the OviTex Reinforced Tissue Matrix (OviTex), addresses unmet needs in hernia repair and abdominal wall reconstruction. Its OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair. The Company's OviTex products include OviTex 1S, OviTex 2S, and OviTex LPR. Its second portfolio of products, the OviTex PRS Reinforced Tissue Matrix (OviTex PRS), addresses unmet needs in plastic and reconstructive surgery. OviTex PRS is indicated for use in implantation to reinforce soft tissue where weakness exists in patients requiring soft-tissue repair.
Símbolo de cotizaciónTELA
Nombre de la empresaTELA Bio Inc
Fecha de salida a bolsaNov 08, 2019
Director ejecutivoMr. Antony Koblish
Número de empleados209
Tipo de seguridadOrdinary Share
Fin del año fiscalNov 08
Dirección1 Great Valley Parkway, Suite 24
CiudadMALVERN
Bolsa de valoresNASDAQ Global Market Consolidated
PaísUnited States of America
Código postal19355
Teléfono14843202930
Sitio Webhttps://www.telabio.com/
Símbolo de cotizaciónTELA
Fecha de salida a bolsaNov 08, 2019
Director ejecutivoMr. Antony Koblish
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.

Sin datos